Coming soon to a screen near you... 👀 In our spring 2025 release, Open Targets Genetics will merge with the Open Targets Platform. Our team has been hard at work, and we're excited to share a sneak preview with you. This merge will provide a deeper integration between the GWAS and functional genomics of Open Targets Genetics, and the target identification and prioritisation tools available in the Open Targets Platform. Take a look!
Open Targets
Research
Hinxton, Cambs 6,700 followers
A partnership using human genetics and genomics data for systematic drug target identification and prioritisation.
About us
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. Open Targets brings together complimentary expertise of our academic and industry partners, Bristol Myers Squibb, EMBL-EBI, Genentech, GSK, Pfizer, Wellcome Sanger Institute, and Sanofi. The freely available Open Targets Platform (platform.opentargets.org) makes it easy for researchers working in many disciplines to identify and prioritise therapeutic targets for new medicines. Open Targets Genetics (genetics.opentargets.org), is our portal for investigation of Genome Wide Association Study (GWAS) data to assist in identifying the causal genes to prioritise drug targets. The portal aggregates and merges genetic associations curated from literature and newly-derived loci from UK Biobank andn FinnGen with (open source) functional genomics data including epigenetics (e.g., chromatin conformation, chromatin interactions) and quantitative trait loci (e.g., eQTLs from GTEX, pQTL), and applies statistical fine-mapping across thousands of trait-associated loci, to resolve association signals and link each variant to its proximal and distal target gene(s), using a single evidence score. Open Targets complements data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation, and is committed to sharing its data openly with the scientific community.
- Website
-
http://www.opentargets.org
External link for Open Targets
- Industry
- Research
- Company size
- 201-500 employees
- Headquarters
- Hinxton, Cambs
- Type
- Partnership
- Founded
- 2014
- Specialties
- Bioinformatics, Target identification, Genetics, Genomics, and Target prioritisation
Locations
-
Primary
Get directions
Wellcome Genome Campus
Hinxton, Cambs CB10 1SD, GB
Employees at Open Targets
-
Ian Dunham
Formerly Director at Open Targets
-
Gosia Trynka
Science Director at Open Targets and Group Leader at Sanger Institute
-
David Ochoa
Target discovery | Computational Biology | Human Disease Genetics | ML | Cloud computing
-
Emmanouil Athanasiadis
Assistant Professor in Computational Biology and Medical Informatics at University of West Attica (GR) and Visiting Scientist at Open Targets…
Updates
-
Out now in Nucleic Acids Research! A look back at all the changes to the Open Targets Platform in the past two years 🖥️ 🧬 We have focused our efforts on adding data and analyses that help to build therapeutic hypotheses, refining the web interface to give you more control over what you see The open source Platform uses publicly available data to identify relationships between drug targets and diseases, and systematically prioritise targets with the ultimate goal of assisting in the development of safer and more effective medicines Take a look!
-
CLOSING: Bioinformatics/data science postdoctoral fellowship with Ewan Birney, working with Ellen McDonagh and Moritz Gerstung Build on innovative AI approaches to define gene x drug exposure x phenotype relationships at scale over continuous time in large human cohorts Drive specific aspects of this cutting-edge research, including the analysis of population scale genetic cohorts with electronic healthcare and prescriptions records Apply through the European Bioinformatics Institute by 8 December
NEW: Postdoctoral Fellow in the Birney research group The project is based in Birney Research group at European Bioinformatics Institute | EMBL-EBI and working closely with Open Targets and Moritz Gerstung's group at DKFZ German Cancer Research Center.
-
-
Muzlifah Haniffa and Mo Lotfollahi are recruiting! 🔎 If you know your way around hiPSCs, molecular biology, and ideally, in vitro infection models, and you're interested in developing your computational skills, this is the role for you. Apply through the Wellcome Sanger Institute by 10 January.
-
-
How do you know whether modulating a target will be beneficial for a disease? 🧬 Bioinformatician Juan María Roldán Romero gives us a walkthrough of the Direction of Effect assessments released to the Open Targets Platform earlier this year Direction of effect describes the relationship between a gene and a trait, including both the functional consequence of the perturbation on the gene, and how this affects the manifestation of the trait Watch the full walkthrough: https://lnkd.in/eWQCjx3z Are there other assessments you want to see in the Platform? #targetidentification #drugdiscovery
-
New digs! The Open Targets team moved into European Bioinformatics Institute | EMBL-EBI's new Thornton Building, built for collaboration.
-
-
"The challenge for us is — within the increasingly vast range of available data and rapidly evolving analysis methods — deciding how and where to implement the most relevant frameworks (...)" 🧬 Meet Yakov Tsepilov, our Genetic Analysis Team leader! #MeetTheTeam
-
"The glorious thing about Open Targets is that it was integration for a purpose." Dame Janet Thornton describes how she came up with the idea for the Open Targets Platform. This clip is from a panel discussion featuring Open Targets' founders, filmed during our 10 year celebrations. The full panel discussion is available to watch on YouTube: https://lnkd.in/euZmjGJt #OpenTargetsAt10